Olaparib Powder CAS 763113-22-0 Olaparib Antineoplastic Olaparib Powder Pharmaceutical Intermediate Olaparib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Certification: GMP, ISO 9001, USP, BP
• Suitable for: Adult
• State: Powder
• Purity: >98%
• Sample: Available
• OEM: Available
• MOQ: 1kg
• Keyword 1: Olaparib
• Keyword 2: Olaparib Powder
• Storage: Dry and Cool Place
• Transport Package: Foil Bag/25kg Drum
• Specification: 98%
• Trademark: /
• Origin: China
• Production Capacity: 10000

Product Description

Description
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair.Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy.

Name	Olaparib
Grade	Pharmaceutical Grade
Appearance	white powder
Specification	98%

Function
Olaparib as a maintenance therapy or monotherapy for the treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. On January 12, 2018, FDA expanded the approved use of Olaparib to include chemotherapy-experienced patients with germline breast cancer susceptibility gene (BRCA) mutated, human epidermal receptor 2 (HER2)-negative metastatic breast cancer.
Application
Olaparib is an anti-tumor targeted therapy drug, which kills cancer cells mainly by synthesizing a lethal mechanism.It is mainly used clinically for the treatment of advanced epithelial ovarian cancer.